Aquatic Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Aquatic Capital Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$99.4K	Sell	1,580 -7,405	-82%	-$473K	﹤0.01%	1088
2026 Q1	$630K	Buy	+8,985	New	+$628K	0.02%	687
2025 Q3	–	Sell	-36,354	Closed	-$1.47M	–	1661
2025 Q2	$1.47M	Buy	+36,354	New	+$1.64M	0.03%	555
2024 Q3	–	Sell	-4,700	Closed	-$128K	–	1530
2024 Q2	$128K	Sell	4,700 -2,500	-35%	-$84.1K	﹤0.01%	845
2024 Q1	$262K	Buy	7,200 +2,500	+53%	+$73.5K	0.01%	701
2023 Q4	$95K	Buy	+4,700	New	+$78.5K	﹤0.01%	1018
2023 Q2	–	Sell	-400	Closed	-$5K	–	1734
2023 Q1	$5K	Buy	+400	New	+$5.85K	﹤0.01%	1165

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aquatic Capital Management's TARS Position: Q2 2026 in Review

Aquatic Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 82% in Q2 2026, selling an estimated $473K and leaving 1,580 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Aquatic Capital Management first reported a position in TARS in Q1 2023 and has held it in 7 quarters since. The position peaked at $1.47M in Q2 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Aquatic Capital Management held 1,580 shares of Tarsus Pharmaceuticals worth $99.4K as of Q2 2026.
Aquatic Capital Management sold 7,405 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $473K.
Tarsus Pharmaceuticals made up ﹤0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #1088 holding.
Aquatic Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Aquatic Capital Management's Tarsus Pharmaceuticals position peaked at $1.47M in Q2 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.